TMX3

Across TCGA pan-cancer cohorts, TMX3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TMX3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMX3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMX3 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where TMX3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMX3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.682	<.001	12	view →
HNSC	Male	II,III,IV	+0.192	<.001	8	view →
PDAC	All	II,III,IV	+0.280	<.001	6	view →
LUAD	All	II,III,IV	−0.178	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TMX3–CCRCC

Open the CCRCC breakdown →